Business
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced it has successfully ...
About this update from Revelation Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced it has successfully reached a quorum for its Special Meeting scheduled for December 3, 2025. As a reminder, if you have not yet voted you have until 11:59pm ET tomorrow, December 2, 2025, to vote.","length":445,"tagName":"p"},{"type":"text","content":""I would like to thank all those that have voted for the December 3, 2025, Special Meeting and remind all those who have not yet voted to vote," said James Rolke, Chief Executive Officer, Revelation.","length":209,"tagName":"p"},{"type":"text","content":"On November 20, 2025, Revelation Biosciences announced its successful submission and acceptance of the end-of-phase 1 meeting package to FDA, and that the company is on track to hold the meeting later this year. The primary purpose of this meeting is to establish agency feedback and input into the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI).","length":408,"tagName":"p"},{"type":"text","content":"On November 6, 2025, the company reported its financial results for the three and nine months ended September 30, 2025. Highlights include groundbreaking top-line results from the PRIME clinical study and gross proceeds of $9.6 million from warrant inducement in September 2025.","length":278,"tagName":"p"},{"type":"text","content":"About Revelation Biosciences, Inc.","length":34,"tagName":"p"},{"type":"text","content":"Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including the treatment of chronic kidney disease, prevention for post-surgical infection and as a treatment for acute kidney injury.","length":343,"tagName":"p"},{"type":"text","content":"For more information on Revelation, please visit www.RevBiosciences.com.","length":72,"tagName":"p"},{"type":"text","content":"Forward-Looking Statements","length":26,"tagName":"p"},{"type":"text","content":"This press release contains forward-looking statements as defined in the Private Securities Litigation Reform ...